Home » Authors » Jim Shrine

Articles by Jim Shrine

Labopharm Falls 50 Percent On Second FDA Approvable Letter

June 4, 2007

Cypress Raises $72.9M Publicly Following Phase III Trial Success

June 1, 2007

Cypress Raises $72.9M Publicly Following Phase III Trial Success

June 1, 2007

Gilead Reports Positive Phase III Results On CF Drug; Plans NDA

May 31, 2007

Gilead Reports Positive Phase III Results On CF Drug; Plans NDA

May 31, 2007

Allon Completes C$15M Funding For Neurodegenerative Programs

May 30, 2007

Allon Completes C$15M Funding For Neurodegenerative Programs

May 30, 2007

Avalon Raises $20M Privately To Fund Drug Development

May 29, 2007

Avalon Raises $20M Privately To Fund Drug Development

May 29, 2007

Celldex Starts Phase II/III Trial Of Peptide Vaccine In Brain Cancer

May 25, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...